Ibuprofen

Dada Announces Unaudited Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Mercoledì, Marzo 8, 2023
Research, Acquisition, Mask, Share repurchase, BBB, Investment, Marketing, Growth, ESG, MSCI, Pharmacy, COVID-19, City, PIN, COVID, Philosophy, New Year, GMV, Advertising, Ecosystem, Government, Chinese New Year, BB, JDDJ, Ibuprofen, Environment, CSA, Cryptocurrency, Pharmaceutical industry, Bank, Mobile phone, Internet service provider

Net revenues generated from Dada Now increased by 11.9% from RMB2,820.7 million in 2021 to RMB3,157.6 million in 2022.

Key Points: 
  • Net revenues generated from Dada Now increased by 11.9% from RMB2,820.7 million in 2021 to RMB3,157.6 million in 2022.
  • Net loss attributable to ordinary shareholders of Dada was RMB2,008.0 million, compared with RMB2,471.1 million in 2021.
  • As of early February, a total of nearly RMB100 million of incentives and subsidies were distributed to Dada Now riders.
  • For the first quarter of 2023, Dada expects total revenue to be between RMB2,570 million and RMB2,770 million, representing year-over-year growth of 27% to 37%.

Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets

Retrieved on: 
Mercoledì, Marzo 1, 2023
Marketing, Ibuprofen, IRI, Safety, Perrigo, NYSE, Tablet, OTC, FDA, Paracetamol, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PRGO, ANDA, Consumer, Abbreviated New Drug Application, Food, Generic drug

DUBLIN, March 1, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the store brand over-the-counter ("OTC") equivalent of Advil® Dual Action Tablets 250 mg/125 mg.

Key Points: 
  • DUBLIN, March 1, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the store brand over-the-counter ("OTC") equivalent of Advil® Dual Action Tablets 250 mg/125 mg.
  • This approval was received on the first day possible following the expiration of the marketing exclusivity for Advil® Dual Action Tablets 250 mg/125 mg."
    Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg provides relief for multiple pain related symptoms by combining two ingredients indicated for OTC pain relief.
  • Retail sales for the national brand equivalent product for the last twelve months ending January 29, 2023, were approximately $69 million based on IRI multi-outlet market data.
  • Important safety information about Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg
    Before using the product, consumers should read the Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg drug facts label.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

Retrieved on: 
Martedì, Febbraio 28, 2023
Skin, Infection, Helicobacter pylori, Pain, Rheumatology, Fever, Vomiting, Gastroenterology, Acetylcysteine, FDA, Patient, Paracetamol, Methotrexate, Systemic-onset juvenile idiopathic arthritis, Nausea, Health, Lactulose, PIN, Multimedia, Amoxicillin, Psoriatic arthritis, Omeprazole, Hyponatremia, Clarithromycin, Constipation, Fungal infection, Ibuprofen, Vaccine, Pharmaceutical industry, Online shopping

NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.

Key Points: 
  • NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.
  • A conference call will be held March 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in the Mid-South and is focused on the delivery of high-quality, prescription brands designed to improve patient care.

Consumer Drones Market Report 2022: Significant Cost Reductions to Bolster Growth - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Gennaio 26, 2023
Technology, Hardware, Automation, Bandage, Federal Aviation Administration, Government, Internet of things, Photography, Health, Intelligence, USD, City, Ibuprofen, FAA, Bangalore, Growth, Walmart, Environment, Zip line, Semiconductor, Jet fuel

Moreover, the significant reduction in the cost of drones, easy operability, and the ability to carry more weight has boosted the market growth too.

Key Points: 
  • Moreover, the significant reduction in the cost of drones, easy operability, and the ability to carry more weight has boosted the market growth too.
  • However, the existence of rules and regulations regarding the use of drones is acting as a restraint in the growth of the consumer drone market.
  • Increasing awareness and availability of consumer drones, high-resolution image and video capturing coupled with advancement in drone technologies are prominent factors driving the growth of the consumer drones market over the analyzed period.
  • All these developments and regulations in the region are thus expected to drive substantial growth in the consumer drone market.

Consumer Drones Market Report 2022: High Resolution Image Capturing and Widespread Availability Drive $12 Billion Industry

Retrieved on: 
Venerdì, Gennaio 27, 2023
USD, Ibuprofen, Federal Aviation Administration, FAA, Automation, Intelligence, Health, Walmart, Environment, Government, Growth, Internet of things, Zip line, Bangalore, City, Bandage, Photography, Jet fuel

DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Consumer Drones Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Consumer Drones Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The consumer drones market was valued at US$4.231 billion in 2020 and is expected to grow at a CAGR of 16.69% over the forecast period to reach a market size of US$12.463 billion in 2027.
  • However, the existence of rules and regulations regarding the use of drones is acting as a restraint in the growth of the consumer drone market.
  • Increasing awareness and availability of consumer drones, high-resolution image and video capturing coupled with advancement in drone technologies are prominent factors driving the growth of the consumer drones market over the analyzed period.

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Giovedì, Gennaio 26, 2023
New Drug Application, Ibuprofen, LAS, United Kingdom, Fever, VAS, X-ray, Insomnia, Methoxyflurane, FDA, MRI, Hypoesthesia, Disease, IASP, Pain, Sufentanil, Trauma, Spasm, Paracetamol, Vertex, Patient, Depression, International Association, Medication, Weight loss, NDA, Abdominoplasty, MVP, International Association for the Study of Pain, Pregabalin, CT, Greatest Hits (Throbbing Gristle album), Fatigue, Inflammation, Ketorolac, VRS, Combustion, Chills, POC, Cough, Anxiety, Vertex Pharmaceuticals, TLC, Pharmaceutical industry, Dietary supplement, Poultry farming

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Giovedì, Gennaio 26, 2023
New Drug Application, Ibuprofen, LAS, United Kingdom, Fever, VAS, X-ray, Insomnia, Methoxyflurane, FDA, MRI, Hypoesthesia, Disease, IASP, Pain, Sufentanil, Trauma, Spasm, Paracetamol, Vertex, Patient, Depression, International Association, Medication, Weight loss, NDA, Abdominoplasty, MVP, International Association for the Study of Pain, Pregabalin, CT, Greatest Hits (Throbbing Gristle album), Fatigue, Inflammation, Ketorolac, VRS, Combustion, Chills, POC, Cough, Anxiety, Vertex Pharmaceuticals, TLC, Pharmaceutical industry, Dietary supplement, Poultry farming

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Child Care Can Lead to Physical Soreness. Proflexa Provides Welcome Relief.

Retrieved on: 
Martedì, Gennaio 24, 2023
Healing, Nonsteroidal anti-inflammatory drug, Ibuprofen, Thumb, Inflammation, Child, Pain, Human, Hip, Aspirin, Skeletal muscle, Father, The New York Times, Infant, Parent, Relief, Birth control

FORT LAUDERDALE, Fla., Jan. 24, 2023 /PRNewswire/ -- The shift to parenthood can be intense. The mind, body, and soul must adjust to the sudden demand of being relied upon around the clock by another human being. One area that tends to quietly cause a significant amount of strain is the need to hold a baby for hours throughout the day.

Key Points: 
  • One area that tends to quietly cause a significant amount of strain is the need to hold a baby for hours throughout the day.
  • The New York Times highlights other factors that lead to this " repetitive stress " on a new parent's body, such as holding a child the entire time they're being fed.
  • Most parents struggle with physical pain on some level as they care for their newborns and infants.
  • Proflexa offers a safe, natural, and extremely effective way to manage that pain on a daily basis without resorting to stronger, potentially dangerous pain-relief solutions.

DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease

Retrieved on: 
Lunedì, Gennaio 23, 2023
Visual analogue scale, MD, Safety, University, NSAID, University of Tennessee Health Science Center, Ibuprofen, Low back pain, AACN Advanced Critical Care, Minimal important difference, Neurosurgery, Conference, North American Spine Society, Pain, Spine, VAS, IDCT, Cell, Aspirin, Trial of the century, FDA, Annual general meeting, MCID, American Academy, Synthetic control method, MRI, Philippine Orthopedic Center, NASS, Disability, ODI, Quality of life, Patient, SALT, DDD, Medical imaging, Birth control, Nursing, Pharmaceutical industry, Tissue, Intervertebral disc

SALT LAKE CITY, Jan. 23, 2023 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).

Key Points: 
  • SALT LAKE CITY, Jan. 23, 2023 /PRNewswire/ -- DiscGenics, Inc. , a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).
  • In the low dose IDCT group (3,000,000 cell/mL; n=20), there was a trend in improvement of clinical outcomes, though inconsistent.
  • The 60-subject study was designed to evaluate the safety and preliminary efficacy of IDCT for the treatment of symptomatic lumbar degenerative disc disease versus vehicle and saline controls.
  • DiscGenics has submitted a full clinical study report to the U.S. Food & Drug Administration's (FDA) Office of Tissues and Advanced Therapies (OTAT).

Practice Winter Wellness with Tips from Pediatric ENT and Dr. Noze Best Founder

Retrieved on: 
Mercoledì, Gennaio 4, 2023
Medical Devices, Parenting, Infectious Diseases, Children, Baby, Maternity, Family, Health, Consumer, General Health, Wheeze, Hospital, Late, Degenerative disease, RSV, Child, Congestion, Alertness, COVID-19, Virus, Dehydration, Disease, ENT, Breathe Me, Learning, Mayo Clinic, Nose, Paracetamol, Suction, Parent, Lip, Human, Drinking, Clinical professor, Tears, Ibuprofen, Fever, Toy, Health insurance, Residential care

, esteemed pediatric ENT, and founder and Chief Medical Officer of Dr. Noze Best , shares his advice to help families practice wellness this winter—and year-round.

Key Points: 
  • , esteemed pediatric ENT, and founder and Chief Medical Officer of Dr. Noze Best , shares his advice to help families practice wellness this winter—and year-round.
  • “For infants and young children, respiratory illnesses can become very serious,” says Dr. Goudy.
  • As RSV and flu continue to spread this winter, parents can take steps to avoid hospital visits and keep their families well.
  • For more resources about treating RSV and other respiratory illnesses from Dr. Goudy and his team, visit www.drnozebest.com/blogs/the-doctor-is-in